Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AXNX

Axonics (AXNX) Stock Price, News & Analysis

Axonics logo

About Axonics Stock (NASDAQ:AXNX)

Advanced Chart

Key Stats

Today's Range
$70.98
$70.98
50-Day Range
$69.66
$70.98
52-Week Range
$66.59
$71.05
Volume
N/A
Average Volume
406,171 shs
Market Capitalization
$3.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Stock News Headlines

Axonics Modulation Technologies Merges and Delists from Nasdaq
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Boston Scientific Closes Acquisition of Axonics, Inc.
See More Headlines

AXNX Stock Analysis - Frequently Asked Questions

Axonics, Inc. (NASDAQ:AXNX) released its quarterly earnings data on Thursday, November, 7th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. The company's quarterly revenue was up 24.8% on a year-over-year basis.

Axonics (AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Axonics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), NVIDIA (NVDA), TotalEnergies (TTE) and The RMR Group (RMR).

Company Calendar

Last Earnings
11/07/2024
Today
5/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AXNX
Employees
610
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
322.64
P/E Growth
N/A
Net Income
-$6.09 million
Pretax Margin
-0.70%

Debt

Sales & Book Value

Annual Sales
$366.38 million
Cash Flow
$0.13 per share
Price / Cash Flow
561.96
Book Value
$12.59 per share
Price / Book
5.64

Miscellaneous

Free Float
50,163,000
Market Cap
$3.63 billion
Optionable
Optionable
Beta
0.82
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:AXNX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners